Ribozymes for treating hepatitis C
US6107027A · kind A · utility
12Cited by
9References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 11, 1995 |
| Grant date | Aug 22, 2000 |
| Priority date | — |
| Expiry date | Sep 11, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/027
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Adenoviral vectors are used for high efficiency transduction of ribozymes specific for hepatitis C virus RNA. Hepatocytes are transduced with a recombinant adenovirus vector that expresses a ribozyme capable of specifically cleaving HCV RNA. The compositions and methods thus provide new means for treating HCV, and further provide transgenic non-human animals having human hepatocytes which are useful in models of HCV disease for developing therapeutic and preventative agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.